The PharmAccess Leaders Forum is Europe’s most respected event for stakeholders involved in achieving patient access for innovative medications. Attendees from the global pharmaceutical industry, payers, health technology assessors, physicians and patient groups, all come together to listen to the opinions of thought-leaders, to network with experts from different perspectives and to achieve actionable insights in this challenging area. The major themes include issues like understanding what is “value” in the eyes of payers and patients, as well as how stronger evidence can be developed and communicated so that budget holders can be more effective in decision making. The overall goal is to ensure that there is rapid access to innovative yet effective medicines, in a budget-effective manner and health-outcomes can be improved to enhance the lives of patients.

Download agenda here for complete speaker list

EXTERNAL STAKEHOLDERS

Deputy Regional Medical Director
NHS England North

Clinical professor
Rutgers State University of New jersey,
Director of Pharmacy Strategy and Clinical Integration
Horizon Blue Cross Blue Shield of New Jersey, USA

Treatment Information and Access Director, Health Policy Advisor
EURORDIS

President, 
European Medical Association

Vice President of Innovation
PatientsLikeMe

Research Professor of Medicine
The University Hospital of Catania

Consumer Lead, Chair, Consumer Forum
National Cancer Research Institute

Senior Vice President & Secretary General, 
European Society for Person Centered Healthcare (ESPCH)

President
European Union of Private Hospitals, (UEPH)

Advisor to the President, Director, International Affairs
HAS, Haute Autorité de Santé, France (TBC)

Honorary Industrial Ambassador in Regulatory Science
The University of Copenhagen, Denmark

CEO
Patient View

Director General, European Confederation of Pharmaceutical Entrepreneurs
Partner,  NOVACOS Law, Germany

Director, Technical Communication and Strategy
Wolfram Research

INDUSTRY

Chief Financial Officer
UCB

Vice President, Head of Operations and Payer Intelligence, Global Market Access
Sanofi

Global Head Operations, Payer & Real World Evidence
AstraZeneca

Director of Real World Evidence, Global Patient Outcomes and Real World Evidence, International
Eli Lilly and Company

Senior Medical Officer, Vice President, Global Medical Affairs
Sanofi

Scientific Director, RMEDS, Quantitative Sciences
Janssen

Global Head of Real World, Evidence Solutions
Novartis

SVP, Head of Clinical Development,
BTG International

Vice President, Head Global Clinical Science & Operations
UCB

Head Patient Relations
Bayer

Vice President, Medical Affairs
Norgine

Senior Vice President, Global Patient Solutions,
Teva

VP, Head of Region Europe
Value Demonstration & Access
Shire International

 

 

Download agenda here for complete speaker list
Download agenda here for complete speaker list

PAYERS & HTA AGENCIES

Clinical professor
Rutgers State University of New jersey,
Director of Pharmacy Strategy and Clinical Integration
Horizon Blue Cross Blue Shield of New Jersey, USA

Head of the Division of Medicines and Remedies
GKV – Spitzenverband, Germany

Senior Scientific Adviser of the Pharmaceuticals Department,
G-BA (Federal Joint Committee), Germany

Technical Adviser – Scientific Advice
NICE - National Institute for Health and Care Excellence, UK

Director,
The National Center for HTA, The National Institute of Health, Ministry of Health, Italy

Global Head of Employee Benefits & Health
AXA Global Life, France

Pharmacist, Head of Business Unit Prescription Management
KVWL, Kassenärztliche Vereinigung Westfalen-Lippe, Dortmund 

Honorary Research Fellow, Usher, Institute of Population Health Sciences and Informatics,
University of Edinburgh, Scotland
Member of the Scottish HTA appraisal committee for non-medicines HTA

Programme Director – Digital Control Centre
Salford Royal NHS Foundation Trust, UK
 

INDEPENDENT THOUGHT LEADERS

Managing Director Science & Policy,
Faculty of Health Sciences, University of Southern Denmark,
Former EUnetHTA Executive Committee Chairman and EUnetHTA Secretariat Director

Partner,
NOVACOS Law, Germany
Director General,
European Confederation of Pharmaceutical Entrepreneurs

PATIENT ADVOCATES

Treatment Information and Access Director, Health Policy Advisor
EURORDIS, France

 

INDUSTRY EXPERTS

VP, Head of Region Europe Value Demonstration & Access
Shire International, Switzerland

Vice President, Head Global Pricing and Market Access / Advocacy
Vifor Pharma, Switzerland

Director, Regional Market Access & Pricing Lead - EMEAC, Patient Value Operations
UCB, Belgium

Head of Program Realization, Global Market Access
Takeda Pharmaceuticals, Switzerland

Lead Evidence & Value, Market Access & Public Affairs
Takeda Pharma, Germany

Senior Director, Life Cycle Management, Global Specialty Medicines 
TEVA, Belgium

Director of Real World Evidence, Global Patient Outcomes and Real World Evidence International
Eli Lilly and Company, Belgium

Health Economics and Outcomes Research Leader
Mundipharma International

Head of Market Access & Healthcare Affairs
Boehringer Ingelheim, Germany

Director, Country Market Access Head
Sanofi, Italy

Health Economics Advisor
Medicines for Europe, Belgium

Director Health Economics and Outcomes
Plasma Protein Therapeutics Association (PPTA) Europe, Belgium

 

EXPERIENCED SOLUTION PROVIDER

Principal, Consulting Services
QuintilesIMS

Senior Principal and EU Lead, Pricing and Market Access
QuintilesIMS, UK 

Director, Strategic Consulting
Truven Health Analytics an IBM Company, USA

Vice President
GFK, UK

Founder & Senior Consultant
PDCI Market Access

Head of Market Access Solutions
Pope Woodhead and Associates Ltd.

Head of Digital Solutions
Pope Woodhead and Associates Ltd.

Managing Director
Pope Woodhead & Associates, UK

 

Download agenda here for complete speaker list

Pictures from recent PharmAccess Leaders Forums. Imagine being there...

Streamlining the dialogue between the pharmaceutical industry and key stakeholders, to increase innovation and deliver patient value.

The PharmaValue Stakeholder Forum is a truly special event and unique discussion format. It focuses on the issues most critical to the future viability of the pharmaceutical industry, which has a strong track record in developing lifesaving drugs for patients. NextLevel LifeSciences is bringing together a unique mix of thought leaders from patient and doctors representatives, payers, health technology assessors, regulators and senior executives from key departments in pharma companies. There will be no presentations, but only interactive panel discussions on 5 of the most challenging areas faced by those who care passionately for medical innovation. These discussions will be:

• Stimulating Innovation in Clinical Research

• Unlocking the Potential of Real-World and Patient-Level Data

• Achieving Value-Based Patient Access

• Enhancing Patient-Centricity in Practice

• The Future of Pharma: Evolution or Revolution?

This is a must attend event for those who feel that the current model is unsustainable and who wish to brainstorm ideas with thought-leaders from all stakeholder groups. Participants who join the discussion will jointly come away with realistic and actionable insights to move towards next-generation models and best practices to accelerate innovation and satisfy patient need.

Speaker List - Day 1

CEO,
Patient View

Sector Head & Board Member – Marketing Authorization
Swissmedic, Schweizerisches, Heilmittelinstitut

Senior Vice President & Secretary General,
European Society for Person Centered Healthcare (ESPCH)

Vice President, Head Global Clinical Science &Operations
UCB

SVP, Head of Clinical Development
BTG International

Research Professor of Medicine
The University Hospital of Catania

Global Head of Real World Evidence Solutions,
Novartis

Director of Real World Evidence, Global Patient Outcomes and Real World Evidence, International
Eli Lilly and Company

Vice President of Innovation
PatientsLikeMe

Senior Medical Officer, Vice President, Global Medical Affairs
Sanofi

Scientific Director, RMEDS, Quantitative Sciences
Janssen

Director, Technical Communication and Strategy
Wolfram Research

Deputy Regional Medical Director
NHS England North

Director of Pharmacy Strategy and Clinical Integration
Horizon Blue Cross Blue Shield of New Jersey, USA

Advisor to the President Director, International Affairs
HAS, Haute Autorité de Santé, France

Honorary Industrial Ambassador in Regulatory Science
The University of Copenhagen, Denmark

Global Head Operations, Payer & Real World Evidence
AstraZeneca

Vice President, Head of Operations and Payer Intelligence, Global Market Access,
Sanofi

VP, Head of Region Europe Value Demonstration & Access
Shire International, Switzerland

Treatment Information and Access Director, Health Policy Advisor
EURORDIS

Consumer, Lead, Chair, Consumer Forum
National Cancer Research Institute

President
European Medical Association

Head Patient Relations
Bayer

Vice President, Medical Affairs
Norgine

Chief Financial Officer
UCB

Senior Vice President, Global Patient Solutions
Teva

Global Head Operations, Payer & Real World Evidence
AstraZeneca

Director General,
European Confederation of Pharmaceutical Entrepreneurs,
Partner,
NOVACOS Law, Germany

President
European Union of Private Hospitals (UEPH)


 

Enhancing evidence-based decision making, to prioritise reimbursement, achieve budget effectiveness and patient access

“Payers” (health plans, sick funds & insurers, payers, health technology assessors, hospital financial management & health department officials) in almost all circumstances, in both developed and developing countries are under extreme budgetary pressure. Many health systems in the developed world, face ageing populations, economic crisis and rapidly increasing healthcare costs in general, including the sustained cost increases of innovative and novel drugs. This is forcing payers to make difficult choices regarding which medical procedures & medications to fund and reimburse. No longer are “me too” drugs that have achieved regulatory approval simply approved for reimbursement at high prices. Payers need to make tough decisions based on what they define as “value”, unfortunately sometimes at the expense of funding treatments in some “lower priority” disease indications or individual patients. Despite intense political pressure from patients and stakeholders who believe healthcare is an inalienable “right” and should be “free for all,” the reality is that payers have a finite and limited budget, and face a high-degree of risk in decision making. They operate within an environment where a multitude of products are on offer, each making various therapeutic claims of efficacy and safety, often with insufficient data to validate supposed health outcome improvements over existing treatment options. How can payers make the right decision in a high-risk, high uncertainty environment? Various options and decision-making tools exist, some old, some novel. Traditional decision making based on, for example, price referencing, DRGs budgets or generic substitution are still significant. However, recent advances in the sophistication of HTA analysis and modeling, flexible pay for performance models, risk-sharing and value-based pricing schemes have become increasingly important to mitigate payer risk and allocate financial resources to the areas of pressing need. Savings and outcome improvements can also be found through finding efficiency gains at the healthcare delivery level, providing the right incentives for prescribers and improving patient adherence.

Why this meeting?

This meeting will provide an ideal opportunity for “payers” and other decision makers from both public and private organisations, to benchmark with peers internationally and provide pharma companies an invaluable insight into the decision making processes and approaches of these vital stakeholders. Attendees will be able to understand and develop best practice approaches to such vital and common challenges, with the ultimate goal of encouraging innovation and improving patient access to novel and powerful medications.

 

Speaker List - Day 2

Senior Principal and EU Lead, Pricing and Market Access
QuintilesIMS, UK 

Managing Director Science & Policy (sole proprietorship), Faculty of Health Sciences,
University of Southern Denmark
Former EUnetHTA Executive Committee Chairman and EUnetHTA Secretariat Director

Treatment Information and Access Director, Health Policy Advisor
EURORDIS, France

Senior Scientific Adviser of the Pharmaceuticals Department,
G-BA (Federal Joint Committee), Germany

Principal, Consulting Services
QuintilesIMS

Technical Adviser – Scientific Advice
NICE - National Institute for Health and Care Excellence, UK

Global Head of Employee Benefits & Health
AXA Global Life, France

Clinical professor
Rutgers State University of New jersey,
Director of Pharmacy Strategy and Clinical Integration
Horizon Blue Cross Blue Shield of New Jersey, USA

Director,
The National Center for HTA, The National Institute of Health, Ministry of Health, Italy

Head of Digital Solutions
Pope Woodhead and Associates Ltd.

Programme Director – Digital Control Centre
Salford Royal NHS Foundation Trust, UK

Honorary Research Fellow, Usher Institute of Population Health Sciences and Informatics,
University of Edinburgh, Scotland
Member of the Scottish HTA appraisal committee for non-medicines HTA

 

 

Developing evidence and demonstrating value, to achieve patient access to next generation speciality, biologic and orphan medications

This one-day event will look uniquely at biologics & higher-cost specialty drugs and the market access challenges they face. The issue of generating quality evidence and demonstrating value to global payers, health technology assessors and other key stakeholders is a major challenge for all products, but an acute one for specialty products across many therapeutic areas and specifically oncology. Such drugs may include niche biologics, expensive small molecules, orphan drugs, personalised medicines or biosimilars. This event will look at the overcoming the current challenges which face biologics & specialty medicines developers: Generating strong evidence to demonstrate value; understanding the latest innovative market access techniques & satisfying HTA requirements to build the right dossier. The discussion will focus on the best practices to the major issues which apply to these higher cost specialty medicines including implementing & designing pay-for-performance schemes and working within value-based pricing models to maximise patient access.

Speaker List - Stream 1

Founder & Senior Consultant
PDCI Market Access

Director, Regional Market Access & Pricing Lead - EMEAC, Patient Value Operations
UCB, Belgium

Director, Country Market Access Head
Sanofi, Italy

Vice President,
GFK, UK

Senior Director, Life Cycle Management, Global Specialty Medicines 
TEVA, Belgium

Director, Strategic Consulting
Truven Health Analytics, an IBM Company, USA

Director of Analytics & Data Science,
São João Hospital Center - Porto, Portugal

Health Economics Advisor
Medicines for Europe, Belgium

Honorary Research Fellow, Usher Institute of Population Health Sciences and Informatics,
University of Edinburgh, Scotland
Member of the Scottish HTA appraisal committee for non-medicines HTA

Director Health Economics and Outcomes
Plasma Protein Therapeutics Association (PPTA) Europe, Belgium

Managing Director
Pope Woodhead & Associates, UK

Technical Adviser – Scientific Advice
NICE - National Institute for Health and Care Excellence, UK

 

Understanding and taking advantage of AMNOG experiences, to achieving evidence-led pricing and reimbursement in Germany.

The German Healthcare system is the EU’s largest and best financed, which until few years ago, used free-market pricing and as such has traditionally been a crucial first step in a pharma company’s EU launch strategy. The large number of sick funds combined with the free pricing policy has resulted in an extremely competitive environment for pharmaceutical manufacturers to operate in until now. The “AMNOG” reform, had dramatically altered the paradigm in Germany and has significantly affected pricing and reimbursement procedures, as well as market access overall. Germany is an important market globally, as It has always been an attractive place to launch first in Europe and the effects of significant price cuts can quickly flow-on to other markets via price referencing. Although many pharmaceutical companies have now completed several submissions in the last few years, and have achieved coverage and crucial experience, average prices and reimbursement levels are on average far lower than during the previous free-pricing system. There has been much debate and discussion between authorities such as The G-BA, IQWIG, The GKV, as well as sick funds and the pharmaceutical industry and much experience sharing. Furthermore, and after the ‘’pharma dialogue’’ is concluded with no dramatic updates, there are ongoing questions about the post AMNOG process and the real impact on patient access, pricing and other areas which will remain in debate also in 2018. Although the new ‘’AMVSG’’ law is changing AMNOG partly, it still leaves the pharma industry disappointed. In addition, the need to integrate Real World Evidence in additional benefit assessments and narrowing the gap between RCTs and RWE is a crucial area of discussion for the authorities and pharma manufacturers. As the AMNOG process matures, pharma companies are more-effectively engaging with The GBA and other stakeholders earlier in the clinical development process and receiving scientific advice. However, such advice is non-binding, often not specific or detailed enough during dynamic clinical development and the choice of comparator is often risky as standards of care do change rapidly.

Why this meeting?

To answer and discuss these crucial points, Industry and non-industry stakeholders will meet at this event after several years of AMNOG experience. This will be an excellent opportunity to gain a real understanding of AMNOG in action & how they can best work within this system to achieve the win-win of patient access to high-value medications.

Speaker List - Stream 2

Director General, European Confederation of Pharmaceutical Entrepreneurs Partner,
NOVACOS Law, Germany

Head of Market Access & Healthcare Affairs
Boehringer Ingelheim, Germany

Lead Evidence & Value, Market Access & Public Affairs
Takeda Pharma, Germany

Pharmacist, Head of Business Unit Prescription Management
KVWL, Kassenärztliche Vereinigung Westfalen-Lippe, Dortmund

Head of the Division of Medicines and Remedies
GKV – Spitzenverband, Germany

Optimising departmental structure and skillsets to achieve a more effective, payer-focused market access function

The market access and related functions are more than ever, absolutely critical to the commercial success of a therapy, as well as the pharmaceutical company as a whole. Pharma companies need to build departments and teams to achieve operational excellence and be better prepared to satisfy the needs of both external and internal stakeholders. A strong understanding of key value drivers for such stakeholders, is paramount before “best practice” can be achieved. Only then can the various disciplines such as health economics, outcomes research, pricing & reimbursement, governmental and payer relations, intelligence, health policy, stakeholder management, evidence development etc., be best coordinated to satisfy objectives. The question of how the market access and related functions, can ideally be structured is still a topic of much debate. Clearly it depends on company’s size, priorities and resources, however what is not clear is if evidence-generating functions such as health economics and outcomes research are closer to the commercial side of the business, or closer to medical or clinical affairs. Another question regarding structure is how to achieve the right balance between global standardization and national or even local flexibility. Other than the structure, market access functions need to be resourced with the right mix of talent and skills to achieve objections. There is a war for talent in this space, so effective recruitment, retention, training and talent management are obviously essential. High-impact training programs are required to re-tool the team with tomorrow’s skillsets. Operational excellence cannot be achieved, however, without putting the customer at the centre of everything that the market access team does. Companies that are too introspective or work too much in silos, often fail to focus on what stakeholders really need. Alternatively market access teams that have the capabilities to develop the right evidence that payers, physicians and patients need, and then can effectively communicate the value of the therapy, will give themselves a distinct advantage in the extremely challenging external environment.

Speaker List - Stream 2 (PM)

Managing Director,
Pope Woodhead & Associates, UK

Vice President, Head Global Pricing and Market Access / Advocacy
Vifor Pharma, Switzerland

VP, Head of Region Europe Value Demonstration & Access
Shire International, Switzerland

Head of Market Access Solutions
Pope Woodhead and Associates Ltd.

Head of Program Realization, Global Market Access
Takeda Pharmaceuticals, Switzerland

Director of Real World Evidence, Global Patient Outcomes and Real World Evidence International
Eli Lilly and Company, Belgium

Health Economics and Outcomes Research Leader
Mundipharma International

This event will provide all delegates the chance to meet one another through our many networking opportunities. With pre-event, mid-morning and mid-afternoon breaks as a standard, this event will also feature a complimentary networking dinner for all participants.

This evening will allow you to meet with our expert speaker panel who represent many stakeholder groups in a less formal setting. Our networking lunches will also allow you plenty of time to meet with your peers and colleagues whilst you refuel through the event.

 Payers, HTAs & Policy Makers:

Senior representatives from Payers, health plans & insurers, Public health experts, health technology assessors, hospital financial management, government & health ministry officials, health management and managed care organizations, epidemiology, horizon scanning, scientific advice, pharmacy strategy & budget management.

Industry: Corporate senior management, vice presidents, directors, senior managers in:

Market access, health economics, pricing & reimbursement, health outcomes, government & regulatory affairs as well as those focused on designing studies to achieve value-adding endpoints, such as R&D strategy, clinical development and medical affairs.

Other Stakeholders

Regulatory agencies, key-opinion leaders, independent health economists, health researchers and academics, physicians, patient groups, consultants & solution providers

“Thank you, it was one of the best events I’ve attended!”
Associate Director, Pricing & Market Access
Astellas

“Thank you, that was the best event I have ever attended on this important topic!”
Vice President
Merck-Serono

“I very much enjoyed the event. The conference was so relevant and hands-on that at many times it felt like a training rather than a conference. Especially the high number of payers that made themselves available, for the conference made this a very valuable meeting.”
Market Access Director Europe
Ferring Pharmaceuticals

“I went to speak for NextLevel Pharma and didn’t really know if it would be a good use of time. After, I felt truly honoured to have been asked. Seniors from payers, Government, and Healthcare joined the industry as delegates. Really senior people. Very impressive.”
Vice President, Head of Global Market Access
Novartis

“Very little needs improvement, the NextLevel team are very well organised and clearly work very hard to give attendees a good experience”
Practice Leader, Market Access, Europe
Quintiles

“Thanks a lot for this great conference, I really appreciated being part of it. The location was absolutely great and the presentations very interesting. The presentations were so different and the perspectives so diverse and so international, that even for a payer, being familiar with these topics, it was really interesting and a lot to learn. Great.”
Head of Care Management Development,
D A K - Gesundheit

Event Partners

This event is accredited for CPD (Continuing Professional Development) status

RECEIVE DISCOUNTED FLIGHTS WHEN YOU REGISTER FOR THIS EVENT WITH

Share with Colleagues